WO2023037383 - FORMULATIONS OF IMMUNE CHECK POINT INHIBITORS
National phase entry:
Publication Number
WO/2023/037383
Publication Date
16.03.2023
International Application No.
PCT/IN2022/050801
International Filing Date
07.09.2022
Title **
[English]
FORMULATIONS OF IMMUNE CHECK POINT INHIBITORS
[French]
FORMULATIONS D'INHIBITEURS DU POINT DE CONTRÔLE IMMUNITAIRE
Applicants **
DR. REDDY’S LABORATORIES LIMITED
Inventors
JAYARAMAN, Murali
K GOUD, Saisharan
ASHOK NANKAR, Sunil
RASUL SAYYAD, Asif
LABALA, Suman
INGALE, Mahesh
Priority Data
202141040560
07.09.2021
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1959 | |
| EPO | Filing, Examination, Granting | 11796 | |
| Japan | Filing, Examination, Granting | 2009 | |
| South Korea | Filing, Examination, Granting | 1713 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,217
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to pharmaceutical formulations of antibodies and antigen-binding fragments against human programmed death receptor-1 (PD-1) or programmed death receptor Ligand 1 (PD-Ll), and method for preparing the same. The disclosed formulations are free of sugar or sugar alcohol and stabilizes anti-PD1/anti-PD L1 antibody from lower to higher concentrations rendering it suitable for different modes of administration (subcutaneous/intravenous).[French]
La présente invention concerne des formulations pharmaceutiques d'anticorps et de fragments de liaison à l'antigène contre le récepteur de mort programmée 1 humain (PD-1) ou un ligand de récepteur de mort programmée 1 (PD-L1), ainsi que leur procédé de préparation. Les formulations décrites sont exemptes de sucre ou d'alcool de sucre et stabilisent l'anticorps anti-PD1/anti-PD L1 de faibles concentrations à des concentrations plus élevées, ce qui les rend appropriées pour différents modes d'administration (sous-cutanée/intraveineuse).